2024
Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rateIntegrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study
Thanarajasingam G, Kluetz P, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Noble B, Paludo J, Powers B, Ross J, Ritchie J, Ruddy K, Schellhorn S, Tarver M, Dueck A, Gross C. Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study. BMJ Open 2024, 14: e074030. PMID: 38199641, PMCID: PMC10806877, DOI: 10.1136/bmjopen-2023-074030.Peer-Reviewed Original ResearchConceptsPhysical function assessmentPhysical functionFunctional assessmentEvaluation of physical functionElectronic health record dataEvaluate physical functionHealth record dataSpanish-speaking patientsDigital health technologiesBreast cancerProspective cohort studyClinician-reported outcomesCancer clinical trialsClinical decision-makingStudy questionnairePatient-centred evaluationHealth technologiesMeasure symptomsOncology practiceCohort studyRecord dataPatient's impressionMayo ClinicEnglish-speakingWearable sensors
2023
Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims
Huntington S, Chang H, Fu A, Loefgren C, Lu X. Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims. Blood 2023, 142: 2348. DOI: 10.1182/blood-2023-181909.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationHealthcare resource utilizationAcute myeloid leukemia patientsRetrospective cohort studyIndex dateMyeloid leukemia patientsAML patientsAML diagnosisR patientsDiagnosis codesEconomic burdenPPPM costsCohort studyContinuous enrollmentND patientsLeukemia patientsMedical costsLarge US administrative claims databaseRefractory acute myeloid leukemia patientsHigher healthcare resource utilizationUS administrative claims databaseMore outpatient encountersNon-HSCT patientsNon-transplant recipientsOlder AML patientsStatin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Podoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.Peer-Reviewed Original ResearchConceptsIncidence of thrombosisPolycythemia veraEssential thrombocythemiaStatin useOlder adultsEnd Results-Medicare databasePopulation-based cohort studyArterial thrombotic eventsSurvival of patientsUse of statinsClaims-based studyRisk of thrombosisCardiovascular morbidityCause mortalityTreatment weighting (IPTW) approachCohort studyOlder patientsOverall survivalThrombotic eventsVenous thrombosisPatient populationPrevious registryStatinsTherapeutic strategiesET subgroupThe COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021
Goyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Network Open 2023, 6: e2316642. PMID: 37273206, PMCID: PMC10242428, DOI: 10.1001/jamanetworkopen.2023.16642.Peer-Reviewed Original ResearchConceptsEarly pandemic monthsOral therapyOutpatient infusionsChronic lymphocytic leukemiaHematologic neoplasmsVisit ratesTelemedicine useCohort studyPandemic monthsLymphocytic leukemiaRetrospective observational cohort studyData cutoff datePerson medical careSubsequent cancer outcomesHalf of patientsObservational cohort studyMantle cell lymphomaCOVID-19COVID-19 pandemicNon-Hispanic whitesMedian ageActive treatmentCancer outcomesMultiple myelomaActive patients
2021
Bundling cancer subtypes in value-based care: A pilot analysis of lymphoma episodes in the Oncology Care Model.
Yue A, Chaudhry B, Schleicher S, Huntington S, Lyss A, Connor N, Tran L, Adelson K. Bundling cancer subtypes in value-based care: A pilot analysis of lymphoma episodes in the Oncology Care Model. Journal Of Clinical Oncology 2021, 39: e18850-e18850. DOI: 10.1200/jco.2021.39.15_suppl.e18850.Peer-Reviewed Original ResearchCommunity oncology practicesAcademic medical centerOncology Care ModelEpisode costsWaldenstrom's macroglobulinemiaCare modelCancer subtypesLarge community oncology practiceProportion of subtypesLarge academic medical centerICD-10 diagnosisIntensity of careValue-based careCohort studyClinical featuresCommon subtypeFrequent subtypeOncology practiceLymphoma populationLymphoma subtypesMedical CenterHeterogeneous diseaseInappropriate shiftIndividual subtypesSubtypesRacial, ethnic, and socioeconomic disparities in treatment outcomes in patients (pts) with diffuse large B-cell lymphoma (DLBCL): A U.S. real-world study using a de-identified electronic health record (EHR)-derived database.
Jin Y, Li J, Mun Y, Masaquel A, Hu S, Biondo J, Huntington S. Racial, ethnic, and socioeconomic disparities in treatment outcomes in patients (pts) with diffuse large B-cell lymphoma (DLBCL): A U.S. real-world study using a de-identified electronic health record (EHR)-derived database. Journal Of Clinical Oncology 2021, 39: e18514-e18514. DOI: 10.1200/jco.2021.39.15_suppl.e18514.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaOverall survivalBaseline characteristicsTreatment patternsEastern Cooperative Oncology Group scoreHealth outcomesLarge B-cell lymphomaSimilar disease stageRetrospective cohort studyFirst-line therapyBetter overall survivalDays of diagnosisNon-Hodgkin lymphomaRace groupsB-cell lymphomaYears of ageReal-world studyDe-identified databaseSignificant differencesElectronic health recordsAdvanced diseaseR-CHOPCohort studyNext therapyMedicaid insuranceOverall survival based on oncologist density in the United States: A retrospective cohort study
Malleshappa S, Giri S, Patel S, Mehta T, Appleman L, Huntington SF, Passero V, Parikh RA, Mehta KD. Overall survival based on oncologist density in the United States: A retrospective cohort study. PLOS ONE 2021, 16: e0250894. PMID: 33979399, PMCID: PMC8115849, DOI: 10.1371/journal.pone.0250894.Peer-Reviewed Original ResearchConceptsRetrospective cohort studyHPSA designationOverall survivalCohort studyMedian survivalPrimary careHealth professional shortage area (HPSA) designationsCare servicesShortage Area DesignationEnd Results (SEER) databaseKaplan-Meier methodMetastatic solid cancersMetastatic solid tumorsAmerican Medical Association MasterfileLog-rank testPrimary care servicesAreas of needPatients' median survivalHealth service availabilityHealth care servicesNumber of oncologistsAdult patientsInferior survivalSurveillance EpidemiologyResults database
2019
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†
Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & Lymphoma 2019, 61: 1178-1187. PMID: 31878809, PMCID: PMC7735409, DOI: 10.1080/10428194.2019.1703970.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeExcess blastsRefractory anemiaOverall survival benefitRetrospective cohort studyMedian OSOS benefitRAEB patientsCohort studySurvival benefitTherapy useMyelodysplastic syndromeClinical trialsLower riskMedicare dataPatientsPropensity scoreOlder adultsDiagnosisAnemiaQuartileUnited StatesAssociationEnd resultOSAssociation Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma
Huntington SF, Zhu W, Hoag JR, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma. JNCI Cancer Spectrum 2019, 3: pkz030. PMID: 31360905, PMCID: PMC6649837, DOI: 10.1093/jncics/pkz030.Peer-Reviewed Original ResearchPositron emission tomographyStaging positron emission tomographyDiffuse large B-cell lymphomaLarge B-cell lymphomaLow-value imagingNon-Hodgkin lymphomaLow clinical utilityB-cell lymphomaCohort studyAppropriate imagingGuideline recommendationsConsensus guidelinesCancer careLymphoma subtypesCell lymphomaClinical utilityEmission tomographyRoutine useOlder adultsLymphomaPhysician ownershipPet ownershipTomographyImagingPatientsImpact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network 2019, 17: 211-219. PMID: 30865915, DOI: 10.6004/jnccn.2018.7095.Peer-Reviewed Original ResearchConceptsImpact of hydroxyureaThrombotic eventsEssential thrombocythemiaEffect of hydroxyureaOlder patientsOverall survivalLower riskMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelHigh-risk essential thrombocythemiaProportional hazards regression modelsRetrospective cohort studyRisk of deathSEER-Medicare databaseHazards regression modelsRisk of thrombosisHU usersFrontline therapyCohort studyCurrent guidelinesStudy populationPatientsReal-world settingThrombosisOlder adults
2018
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Advances 2018, 2: 2681-2690. PMID: 30333100, PMCID: PMC6199652, DOI: 10.1182/bloodadvances.2018021436.Peer-Reviewed Original ResearchConceptsRisk of thrombosisPV patientsOverall survivalThrombotic eventsMultivariable Cox proportional hazards modelsEnd Results-Medicare databaseHigh-risk PV patientsCox proportional hazards modelOlder adultsImpact of phlebotomyRetrospective cohort studyPopulation-based studyProportional hazards modelEffect of phlebotomyOutcomes of interestPolycythemia vera patientsContemporary clinical practiceImproved OSCohort studyCytoreductive therapyOlder patientsTherapeutic phlebotomyTreatment modalitiesCurrent guidelinesLower risk
2017
Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life
Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X. Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. Journal Of Clinical Oncology 2017, 35: jco.2017.72.714. PMID: 28783450, PMCID: PMC5648174, DOI: 10.1200/jco.2017.72.7149.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaDays of lifeEnd of lifeLife careHospice careOlder patientsHospice enrollmentMyeloid leukemiaIntensive care unit admissionMultivariable logistic regression analysisOlder adultsLate hospice enrollmentCare unit admissionRetrospective cohort studyUse of chemotherapyIntensive care unitHealth care useLogistic regression analysisYears of ageUnit admissionAggressive treatmentCohort studyOverall cohortAML diagnosisCare unitPhysician volume and discontinuation of rituximab during lymphoma treatment.
Huntington S, Long J, Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma treatment. Journal Of Clinical Oncology 2017, 35: 6593-6593. DOI: 10.1200/jco.2017.35.15_suppl.6593.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaEarly discontinuationRituximab discontinuationPhysician volumeProvider volumeEnd Results-Medicare dataB-cell non-Hodgkin lymphomaCell non-Hodgkin lymphomaCox proportional hazards modelDiscontinuation of rituximabSevere infusion reactionsRetrospective cohort studyImpact of discontinuationDays of initiationProportional hazards modelDose-dependent mannerRituximab cyclesRituximab initiationInfusion reactionsOverall survivalCohort studyPrimary outcomeSystemic treatmentLymphoma treatmentRelative riskHypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study. Journal Of Clinical Oncology 2017, 35: 7057-7057. DOI: 10.1200/jco.2017.35.15_suppl.7057.Peer-Reviewed Original ResearchOverall survivalHR-MDSDiagnosis yearUS population-based analysisEnd Results-Medicare dataHigh-risk myelodysplastic syndromeLarge population-based studyConventional care regimensMedian overall survivalRetrospective cohort studyRisk myelodysplastic syndromesPopulation-based studyRecent registry dataPopulation-based analysisUse of decitabineAZA-001Unselected natureCohort studyConventional careExcess blastsOlder patientsTherapy usePatient selectionSurvival prolongationCare regimens
2016
Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Gore S, Ma X, Davidoff A. Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. Blood 2016, 128: 394. DOI: 10.1182/blood.v128.22.394.394.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaMyelodysplastic syndromeSurvival benefitHigh-risk myelodysplastic syndromeDemonstrated survival benefitRetrospective cohort studyRisk myelodysplastic syndromesUse of HMAsAgent azacitidineLack of evidenceCohort studyClinical entityMyelomonocytic leukemiaBiologic evidenceOlder adultsAzacitidineUnited StatesHMAsEnd resultPatientsSyndromeLeukemiaDecitabineEpidemiologyMyelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study
Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study. The Prostate 2016, 77: 437-445. PMID: 27868212, PMCID: PMC5785924, DOI: 10.1002/pros.23281.Peer-Reviewed Original ResearchConceptsMDS/acute myeloid leukemiaAcute myeloid leukemiaProstate cancer patientsElderly prostate cancer patientsImpact of radiotherapyCancer patientsMyelodysplastic syndromeNational Cancer Institute's SurveillanceSubsequent myelodysplastic syndromeEnd Results-MedicareRetrospective cohort studyRole of radiotherapyInformed treatment decisionsUnderwent radiotherapyIMRT groupCohort studyPatient characteristicsMedian timeMyeloid leukemiaProstate cancerTreatment decisionsPatientsRadiotherapyMyeloid malignanciesSurgery